Investor Relations

About Theravance Biopharma

OUR FOCUS IS ON MAKING A DIFFERENCE

Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.

In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation suspension . Our pipeline of internally discovered programs is targeted to address significant patient needs.

We have an economic interest in potential future payments from Glaxo Group or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY ELLIPTA.

Corporate Presentation

Q2 20
 
 View 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations
08/06/20 at 5:00 PM EDT
Theravance Biopharma Second Quarter 2020 Earnings Results Call
05/06/20 at 5:00 PM EDT
Theravance Biopharma First Quarter 2020 Earnings Results Call

Shareholder Tools